Parties, docket activity and news coverage of federal case Amgen Inc. et al v.
Sanofi et al, case number 1:14-cv-01317, from Delaware Court.
Mar 23, 2016 ... Plaintiff Victoria Cerveny allegedly took Clomid in September and October 1992.
Shortly ... The case name is Cerveny et al v. Sanofi et al.
Amgen Inc. v. Sanofi et al. 1:14-cv-01393; Filed: 11/11/2014; Closed: 01/05/2017;
Latest Docket Entry: 01/05/2017; PACER. Thank you for your request. We will ...
Mar 22, 2016 ... recently, Zhang et al. introduced a different approach to reduce the heterogeneity
in ... In 2014, Sanofi-Genzyme published a combinatorial .... Slamon DJ, Leyland-
Jones B, Shak S, Fuchs H, Paton V,. Bajamonde A, et al. ... Hamblett KJ, Senter
PD, Chace DF, Sun MM, Lenox J, Cerveny. CG, et al. Effects of ...
Mar 22, 2016 ... Very recently, Zhang et al. introduced a different approach to reduce the ... In
2014, Sanofi-Genzyme published a combinatorial approach of ...
Apr 26, 2015 ... Vss=volume of distribution at steady state. tmax=time to reach the maximum
concentration. ..... CD19-targeted maytansinoid antibody–drug conjugate
SAR3419 (Sanofi, Paris, .... 9Francisco, JA, Cerveny, CG, Meyer, DL et al.
... dose rate, the quality of radiation, and the time and extent of bodily exposure (;;
). ..... 2 h after irradiation had lower efficacy than a pre-irradiation injection (i.e., 12
% vs. ..... (sargramostim) is 5–10 μg kg<sup>−1</sup> d<sup>−1</sup> sc or (200–400 μg m<sup>−2</sup> d<sup>−1</sup>) (;).
Feb 27, 2013 ... CD19. Hz IgG1 SPDB. Maytansine DM4 Phase II NHL sanofi. BT062. CD138 .....
Doronina, S.O.; Toki, B.E.; Torgov, M.Y.; Mendelsohn, B.A.; Cerveny, C.G.; Chace,
D.F.;. DeBlanc, R.L.; Gearing, R.P.; Bovee, T.D.; Siegall, C.B.; et al. .... Kovtun,
Y.V.; Goldmacher, V.S. Cell killing by antibody-drug conjugates.
www.reactgroup.org/uploads/react/resources/105/Fighting bacterial infections - Future treatment options.pdf
et al., 2009) and lipohexapeptides (Zhang and Falla, 2010) are all classes .... for
quorum sensing in E. coli and V. cholerae were also identified .... 2010) and
Vibrio vulnificus (Cerveny et al., 2002). .... KaloBios Pharmaceuticals/Sanofi
; D.D. Weisenburger, K.J. Savage, N.L. Harris, et al. .... ; P.L. Zinzani, F.
Venturini, V. Stefoni, et al. .... ; J.A. Francisco, C.G. Cerveny, D.L. Meyer, et al.